Who is sponsoring NCT01235910?

NCT01235910 is sponsored by University of Colorado, Denver.

What condition does NCT01235910 study?

NCT01235910 studies Hypertension, Cardiac Transplantation.

What is the status of NCT01235910?

NCT01235910 is currently TERMINATED.

Last reviewed 2018-05-30 · How we verify

Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation

NCT01235910 Phase 4 TERMINATED Results posted

The purpose of this study is to evaluate the safety and efficacy of the blood pressure medication, aliskiren, in heart transplant patients. In terms of safety, the investigators will evaluate the blood levels of aliskiren and determine if aliskiren alters the blood levels of the anti-rejection medication, cyclosporine, in these patients. In terms of efficacy, the investigators will determine how well aliskiren lowers blood pressure in heart transplant patients.

Details

Lead sponsor	University of Colorado, Denver
Phase	Phase 4
Status	TERMINATED
Enrolment	1
Start date	2011-05
Completion	2012-12

Conditions

Hypertension
Cardiac Transplantation

Interventions

Aliskiren

Primary outcomes

Dose-normalized Cyclosporine Area Under the Plasma Concentration-time Curve (AUC) — 7 days, 14 days, 30 days (End of Study)
The study was stopped due to difficulty finding patients who met the strict inclusion criteria. Only one patient was started on the study drug. as a result we did not analyze any cyclosporine PK (e.g.(AUCs) for this study.

Countries

United States